StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CPRXBullishM&Anews
High materiality9/10

Angelini completes Catalyst deal; CPRX shareholders receive $31.50 cash per share

Jul 16, 2026, 3:39 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The cash offer provides a clear liquidation value for CPRX holders and creates a near-term price anchor near $31.50; however, once closed and delisted, ongoing equity upside disappears, limiting longer-term price impact.

AI summary

What happened, with direct paths to the underlying reporting

Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals, delivering $31.50 in cash per Catalyst share and resulting in CPRX being delisted. The deal is financed by Blackstone (€1B in preferred equity) and CDP Equity (~€1B for a 23.5% Angelini stake), underscoring strong cross-border support for Angelini’s US expansion into Brain Health and Rare Diseases. The transaction solidifies Angelini’s global platform while keeping Italy as a strategic research hub.

  • Angelini Pharma completes Catalyst acquisition; CPRX cash-out at $31.50 per share.
  • Blackstone provides €1B in preferred equity for Angelini's financing.
  • CDP Equity commits ~€1B for 23.5% stake in Angelini Pharma.
  • Catalyst stock exits Nasdaq; CPRX shareholders receive cash and delisting follows.
  • US expansion via Catalyst accelerates Angelini's Brain Health and Rare Diseases platform.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event